Melanoma Clinical Trials in Salt Lake City

Showing 181-200 of 244 trials

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

NCT02014441

The primary objective was to estimate the proportion of participants with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after administration of talimogene laherparepvec within the first 3 cycles.

Melanoma

Amgen61 participantsStarted Apr 2014

Tampa, Florida, United States • Indianapolis, Indiana, United States • Louisville, Kentucky, United States +11 more locations

COMPLETEDPhase 2< 1 mile

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

NCT01636882

This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted from the study drug and who might benefit from further treatment. In order to accommodate those patients further treatment to complete 48 weeks of CVA21 intratumoral injections will be made available.

Melanoma

Viralytics16 participantsStarted Jul 2012

Park Ridge, Illinois, United States • Portland, Oregon, United States • Dallas, Texas, United States +1 more locations

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

Melanoma Trials in Other Cities

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Safety Study of PLX4032 in Patients With Solid Tumors

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

A Study of Vemurafenib in Participants With Metastatic Melanoma

Other Conditions in Salt Lake City